DE602005011784D1 - Pyrazoloä4,3-düpyrimidine - Google Patents

Pyrazoloä4,3-düpyrimidine

Info

Publication number
DE602005011784D1
DE602005011784D1 DE602005011784T DE602005011784T DE602005011784D1 DE 602005011784 D1 DE602005011784 D1 DE 602005011784D1 DE 602005011784 T DE602005011784 T DE 602005011784T DE 602005011784 T DE602005011784 T DE 602005011784T DE 602005011784 D1 DE602005011784 D1 DE 602005011784D1
Authority
DE
Germany
Prior art keywords
düpyrimidine
compounds
formula
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005011784T
Other languages
English (en)
Inventor
Andrew Simon Bell
David Graham Brown
David Nathan Fox
Hwang-Fun Lu
Ian Roger Marsh
Andrew Ian Morrell
Dafydd Rhys Owen
Michael John Palmer
Thomas Edward Rogers
Carol Ann Windslow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0407927A external-priority patent/GB0407927D0/en
Priority claimed from GB0407946A external-priority patent/GB0407946D0/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE602005011784D1 publication Critical patent/DE602005011784D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602005011784T 2004-04-07 2005-03-30 Pyrazoloä4,3-düpyrimidine Expired - Fee Related DE602005011784D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0407927A GB0407927D0 (en) 2004-04-07 2004-04-07 Novel pharmaceuticals
GB0407946A GB0407946D0 (en) 2004-04-07 2004-04-07 Novel pharmaceuticals
US57202404P 2004-05-18 2004-05-18
US57204904P 2004-05-18 2004-05-18
PCT/IB2005/000891 WO2005097799A1 (en) 2004-04-07 2005-03-30 Pyrazolo`4,3-d! pyrimidines

Publications (1)

Publication Number Publication Date
DE602005011784D1 true DE602005011784D1 (de) 2009-01-29

Family

ID=34962202

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005011784T Expired - Fee Related DE602005011784D1 (de) 2004-04-07 2005-03-30 Pyrazoloä4,3-düpyrimidine

Country Status (10)

Country Link
US (1) US7569572B2 (de)
EP (1) EP1742950B1 (de)
JP (1) JP2007532526A (de)
AT (1) ATE417849T1 (de)
BR (1) BRPI0509731A (de)
CA (1) CA2562251C (de)
DE (1) DE602005011784D1 (de)
DK (1) DK1742950T3 (de)
ES (1) ES2317209T3 (de)
WO (1) WO2005097799A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
JP2012506856A (ja) * 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
UY33535A (es) 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US10709341B2 (en) 2012-11-21 2020-07-14 St. Jude Medical Luxembourg Holdings II S.a.r.l. Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment
EP2970124B1 (de) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondriale aldehyd-dehydrogenase-2-modulatoren und verfahren zur verwendung davon
US9198908B2 (en) * 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
EP3140007A1 (de) * 2014-05-05 2017-03-15 Apicore US LLC Verfahren zur herstellung von netupitant und zwischenprodukte davon

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3851980A (en) * 1974-04-19 1974-12-03 L Worth Tubing connector
US3951980A (en) * 1974-05-09 1976-04-20 Stanford Research Institute 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
AU516604B2 (en) 1978-04-03 1981-06-11 Yoshida Kogyo K.K. Tiltable roller assembly
EP0215942B1 (de) 1985-03-15 1995-07-12 Antivirals Inc. Immunotestmittel für polynukleotid und verfahren
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
GB8728483D0 (en) 1987-12-04 1988-01-13 Ciba Geigy Ag Chemical compounds
US5091431A (en) * 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
FR2638745B1 (fr) 1988-11-08 1994-01-14 Synthelabo Derives de ((n-alkylthioalkyl-methylamino)-2 ethyl)-5 benzothiazepine-1,5 one-4, leur preparation et leur application en therapeutique
US4994460A (en) 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
JPH03142277A (ja) 1989-10-30 1991-06-18 Fuji Photo Film Co Ltd 記録材料
US5442044A (en) * 1991-01-04 1995-08-15 Pfizer Inc. Orally active renin inhibitors
WO1993001181A1 (en) 1991-07-03 1993-01-21 The Upjohn Company Substituted indoles as anti-aids pharmaceuticals
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
KR100390612B1 (ko) 1997-04-25 2003-07-07 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법
US6184338B1 (en) * 1997-08-27 2001-02-06 Fmc Corporation Anionic polymerization initiators containing tertiary amine functionality, their chain extended analogues, and processes for using the same
HU230154B1 (hu) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
DE19752952A1 (de) 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
AU748352B2 (en) 1998-04-20 2002-06-06 Pfizer Inc. Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
WO2000024745A1 (en) 1998-10-23 2000-05-04 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
US6465486B1 (en) * 1999-03-12 2002-10-15 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl/quinolinyl imidazoles
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CZ20021151A3 (cs) 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
US6548509B2 (en) * 1999-10-22 2003-04-15 Neurogen Corporation 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
GB9930570D0 (en) 1999-12-23 2000-02-16 Pfizer Ltd Therapy
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
EP1244668B1 (de) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
US20010047013A1 (en) * 2000-03-10 2001-11-29 Fengrui Lang Process for the preparation of arylamines
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE60108398T2 (de) 2000-07-28 2005-12-22 Pfizer Inc. Kristallin-therapeutisches mittel
EP1176142A1 (de) 2000-07-28 2002-01-30 Pfizer Inc. Verfahren zur Herstellung von Pyrazolen
YU51701A (sh) 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
CA2419033A1 (en) 2000-08-11 2002-02-21 Earl Michael Gibbs Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
JP2004529859A (ja) 2000-11-20 2004-09-30 サイオス インコーポレイテッド インドール誘導体とｐ３８キナーゼの阻害剤としてのその使用方法
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
WO2002049651A1 (de) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
CZ20032339A3 (cs) * 2001-01-31 2004-09-15 Merck Patent Gmbh Farmaceutický prostředek obsahující parazolo [4,3-d]pyrimidiny a nitráty nebo thienopyrimidiny a nitráty
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
JP2002255932A (ja) 2001-03-01 2002-09-11 Katayama Seiyakushiyo:Kk ３−アルキルアミノアゼチジンの製造方法
US20020127593A1 (en) 2001-03-12 2002-09-12 Regents Of The University Of California Fluorescence assay for DNA modifying enzymes
GB0106631D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US6432957B1 (en) * 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
EP1490015B1 (de) 2002-03-15 2009-09-23 Wayne State University Neue 2-amino-9-((2-hydroxymethyl)cyclopropylidenmethyl)-purine als antivirale mittel
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US7505971B2 (en) 2002-06-28 2009-03-17 Hewlett-Packard Development Company, L.P. Shared drive that provides shared access to editable files in a database
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.

Also Published As

Publication number Publication date
US20080293697A1 (en) 2008-11-27
WO2005097799A8 (en) 2006-02-16
ES2317209T3 (es) 2009-04-16
CA2562251C (en) 2009-04-28
EP1742950B1 (de) 2008-12-17
ATE417849T1 (de) 2009-01-15
JP2007532526A (ja) 2007-11-15
US7569572B2 (en) 2009-08-04
WO2005097799A1 (en) 2005-10-20
CA2562251A1 (en) 2005-10-20
BRPI0509731A (pt) 2007-09-25
EP1742950A1 (de) 2007-01-17
DK1742950T3 (da) 2009-03-16

Similar Documents

Publication Publication Date Title
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
UY29612A1 (es) Compuestos quimicos ii
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
NO20060202L (no) Pyrrolodihydroisokinoliner som PDE-10-inhibitorer
TW200626559A (en) Anilino-pyrimidine analogs
EA201790678A1 (ru) Бициклические гетероарильные соединения
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
WO2007085895A3 (en) Fap inhibitors
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
MX2009007077A (es) Analogos de ciclopamina.
SV2006002001A (es) Inhibidores de quinasa ref. x - 16437
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA201000566A1 (ru) Гетероциклические сетр ингибиторы
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee